Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018

•The susceptibility of 781 Pseudomonas aeruginosa isolates collected from US patients was analysed.•Intensive care unit patients with confirmed or suspected P. aeruginosa pneumonia were included.•Ceftolozane-tazobactam (C/T) was the most active agent (97.2% susceptible).•C/T remained >85% active...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2021-11, Vol.112, p.321-326
Main Authors: Pfaller, Michael A., Shortridge, Dee, Harris, Kelly A., Garrison, Mark W., DeRyke, C. Andrew, DePestel, Daryl D., Moise, Pamela A., Sader, Helio S.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Ceftolozane-tazobactam
Cephalosporins - pharmacology
Cephalosporins - therapeutic use
Coresistance
Drug Resistance, Multiple, Bacterial
Humans
ICU
Intensive Care Units
Microbial Sensitivity Tests
Pneumonia - drug therapy
Pseudomonas aeruginosa
Pseudomonas Infections - drug therapy
Tazobactam - pharmacology
United States
Ventilator-associated pneumonia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The susceptibility of 781 Pseudomonas aeruginosa isolates collected from US patients was analysed.•Intensive care unit patients with confirmed or suspected P. aeruginosa pneumonia were included.•Ceftolozane-tazobactam (C/T) was the most active agent (97.2% susceptible).•C/T remained >85% active against P. aeruginosa that were non-susceptible to empiric β-lactams.•Conversely, other common β-lactams retained
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2021.09.064